LENZ Therapeutics Q3 net loss widens on increased SG&A expenses

LENZ Therapeutics

05/11/2025 13:10

Overview

LENZ Therapeutics Q3 net loss was $16.7 mln, driven by increased SG&A expenses

VIZZ received FDA approval and launched commercially in October 2025

Over 5,000 VIZZ prescriptions filled by October 2025

Outlook

Company to launch VIZZ direct-to-consumer campaign in Q1 2026

LENZ anticipates broad VIZZ availability by mid-Q4 2025

Company did not provide specific financial guidance

Result Drivers

ECP ENGAGEMENT - Over 2,500 unique ECPs prescribed VIZZ, with more than 5,000 prescriptions filled by October 2025

MARKETING STRATEGY - Partnership with Sarah Jessica Parker for a direct-to-consumer campaign launching in Q1 2026

INTERNATIONAL EXPANSION - Licensing agreement with Laboratoires Théa for VIZZ commercialization in Canada

SG&A EXPENSES - Increased to $27.6 million and $51.5 million for the three and nine months ended September 30, 2025, respectively, compared to $6.5 million and $19.5 million during the same periods in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$16.70 mln
Q3 Income from Operations
-$18.88 mln
Q3 Operating Expenses
$31.38 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for LENZ Therapeutics Inc is $53.00, about 47.1% above its November 4 closing price of $28.05

Press Release: ID:nGNX7mXlhl

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)